NeuroSigma to begin PhIII epilepsy device trial

NeuroSigma will begin a Phase III pivotal trial of its Monarch system for the treatment of drug-resistant epilepsy, having received IDE approval from the FDA. The external Trigeminal Nerve Stimulation (eTNS) system consists of an external electric pulse generator and a patch attached to a patient's forehead overnight to stimulate the large cranial nerve through the skin. In Phase I and II trials, over 40% of patients treated with the device showed a 50% or greater reduction in seizures, according to the L.A.-based company. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.